{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T19:23:50Z","timestamp":1748719430969,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s11060-021-03909-1","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T21:29:01Z","timestamp":1638394141000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma"],"prefix":"10.1007","volume":"156","author":[{"given":"Nalee","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5426-0604","authenticated-orcid":false,"given":"Do Hoon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"3909_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/s1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, R\u00f6th A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leith\u00e4user M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, N\u00e4gele T, Pietsch T, Bamberg M, Weller M (2010) High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036\u20131047. https:\/\/doi.org\/10.1016\/s1470-2045(10)70229-1","journal-title":"Lancet Oncol"},{"key":"3909_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3857\/roj.2020.00052","volume":"38","author":"TH Lee","year":"2020","unstructured":"Lee TH, Lee JH, Chang JH, Ye S-J, Kim TM, Park C-K, Kim IH, Kim BH, Wee CW (2020) Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. Radiat Oncol J 38:35\u201343. https:\/\/doi.org\/10.3857\/roj.2020.00052","journal-title":"Radiat Oncol J"},{"key":"3909_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5045\/kjh.2012.47.1.60","volume":"47","author":"JE Kim","year":"2012","unstructured":"Kim JE, Yoon DH, Kim S, Lee DH, Kim JH, Yoon YH, Chi HS, Lee SW, Park CS, Huh J, Suh C (2012) Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma. Korean J Hematol 47:60\u201366. https:\/\/doi.org\/10.5045\/kjh.2012.47.1.60","journal-title":"Korean J Hematol"},{"key":"3909_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","volume":"80","author":"K Jahnke","year":"2006","unstructured":"Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80:159\u2013165. https:\/\/doi.org\/10.1007\/s11060-006-9165-6","journal-title":"J Neurooncol"},{"key":"3909_CR5","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/wnl.0000000000008900","volume":"94","author":"C Houillier","year":"2020","unstructured":"Houillier C, Soussain C, Ghesqui\u00e8res H, Soubeyran P, Chinot O, Taillandier L, Lamy T, Choquet S, Ahle G, Damaj G, Agap\u00e9 P, Molu\u00e7on-Chabrot C, Amiel A, Delwail V, Fabbro M, Jardin F, Chauchet A, Moles-Moreau MP, Morschhauser F, Casasnovas O, Gressin R, Fornecker LM, Abraham J, Marolleau JP, Tempescul A, Campello C, Colin P, Tamburini J, Laribi K, Serrier C, Haioun C, Chebrek S, Schmitt A, Blonski M, Houot R, Boyle E, Bay JO, Oberic L, Tabouret E, Waultier A, Martin-Duverneuil N, Touitou V, Cassoux N, Kas A, Mokhtari K, Charlotte F, Alentorn A, Feuvret L, Le Garff-Tavernier M, Costopoulos M, Mathon B, Peyre M, Delgadillo D, Douzane H, Genet D, Aidaoui B, Hoang-Xuan K, Gyan E (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94:e1027\u2013e1039. https:\/\/doi.org\/10.1212\/wnl.0000000000008900","journal-title":"Neurology"},{"key":"3909_CR6","doi-asserted-by":"publisher","first-page":"8323","DOI":"10.2147\/ott.S192379","volume":"13","author":"M Holdhoff","year":"2020","unstructured":"Holdhoff M, Wagner-Johnston N, Roschewski M (2020) Systemic approach to recurrent primary CNS lymphoma: perspective on current and emerging treatment strategies. Onco Targets Ther 13:8323\u20138335. https:\/\/doi.org\/10.2147\/ott.S192379","journal-title":"Onco Targets Ther"},{"key":"3909_CR7","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/jco.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410\u20132418. https:\/\/doi.org\/10.1200\/jco.2017.72.7602","journal-title":"J Clin Oncol"},{"key":"3909_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2016-01-650101","volume":"128","author":"B Kasenda","year":"2016","unstructured":"Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT (2016) The role of whole brain radiation in primary CNS lymphoma. Blood 128:32\u201336. https:\/\/doi.org\/10.1182\/blood-2016-01-650101","journal-title":"Blood"},{"key":"3909_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/jco.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Molu\u00e7on-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823\u2013833. https:\/\/doi.org\/10.1200\/jco.18.00306","journal-title":"J Clin Oncol"},{"key":"3909_CR10","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/s2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, S\u00f8nderskov G\u00f8rl\u00f8v J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol 4:e510\u2013e523. https:\/\/doi.org\/10.1016\/s2352-3026(17)30174-6","journal-title":"Lancet Haematol"},{"key":"3909_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-021-03815-6","volume":"154","author":"N Kim","year":"2021","unstructured":"Kim N, Lim DH, Yoon SE, Kim SJ, Kim WS (2021) Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy. J Neurooncol 154:207\u2013217. https:\/\/doi.org\/10.1007\/s11060-021-03815-6","journal-title":"J Neurooncol"},{"key":"3909_CR12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1200\/jco.2005.01.161","volume":"23","author":"PL Nguyen","year":"2005","unstructured":"Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23:1507\u20131513. https:\/\/doi.org\/10.1200\/jco.2005.01.161","journal-title":"J Clin Oncol"},{"key":"3909_CR13","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1212\/01.wnl.0000276986.19602.c1","volume":"69","author":"AF Hottinger","year":"2007","unstructured":"Hottinger AF, DeAngelis LM, Yahalom J, Abrey LE (2007) Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology 69:1178\u20131182. https:\/\/doi.org\/10.1212\/01.wnl.0000276986.19602.c1","journal-title":"Neurology"},{"key":"3909_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdq548","volume":"22","author":"NB Khimani","year":"2011","unstructured":"Khimani NB, Ng AK, Chen YH, Catalano P, Silver B, Mauch PM (2011) Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy. Ann Oncol 22:979\u2013984. https:\/\/doi.org\/10.1093\/annonc\/mdq548","journal-title":"Ann Oncol"},{"key":"3909_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/jjco\/hyx095","volume":"47","author":"Y Miyakita","year":"2017","unstructured":"Miyakita Y, Ohno M, Takahashi M, Muragaki Y, Katai H, Narita Y (2017) Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL). Jpn J Clin Oncol 47:919\u2013924. https:\/\/doi.org\/10.1093\/jjco\/hyx095","journal-title":"Jpn J Clin Oncol"},{"key":"3909_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","volume":"100","author":"AK Ng","year":"2018","unstructured":"Ng AK, Yahalom J, Goda JS, Constine LS, Pinnix CC, Kelsey CR, Hoppe B, Oguchi M, Suh CO, Wirth A, Qi S, Davies A, Moskowitz CH, Laskar S, Li Y, Mauch PM, Specht L, Illidge T (2018) Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 100:652\u2013669. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.12.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3909_CR17","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3324\/haematol.2011.060434","volume":"97","author":"C Soussain","year":"2012","unstructured":"Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesqui\u00e8res H, Damaj G, Dupriez B, Vargaftig J, Gonzalez A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond V (2012) Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 97:1751\u20131756. https:\/\/doi.org\/10.3324\/haematol.2011.060434","journal-title":"Haematologica"},{"key":"3909_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3324\/haematol.2012.070839","volume":"98","author":"JE Bromberg","year":"2013","unstructured":"Bromberg JE, Doorduijn JK, Illerhaus G, Jahnke K, Korfel A, Fischer L, Fritsch K, Kuittinen O, Issa S, van Montfort C, van den Bent MJ (2013) Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation\u2013an international primary central nervous system lymphoma study group project. Haematologica 98:808\u2013813. https:\/\/doi.org\/10.3324\/haematol.2012.070839","journal-title":"Haematologica"},{"key":"3909_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12185-013-1403-z","volume":"98","author":"MK Choi","year":"2013","unstructured":"Choi MK, Kang ES, Kim DW, Ko YH, Seok H, Park JH, Pyo DH, Hoon Lim D, Kim SJ, Kim WS (2013) Treatment outcome of relapsed\/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. Int J Hematol 98:346\u2013354. https:\/\/doi.org\/10.1007\/s12185-013-1403-z","journal-title":"Int J Hematol"},{"key":"3909_CR20","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1038\/leu.2017.170","volume":"31","author":"B Kasenda","year":"2017","unstructured":"Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, R\u00f6th A, Bloehdorn J, M\u00f6hle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G (2017) High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German cooperative PCNSL study group. Leukemia 31:2623\u20132629. https:\/\/doi.org\/10.1038\/leu.2017.170","journal-title":"Leukemia"},{"key":"3909_CR21","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/jco.2007.13.5533","volume":"26","author":"C Soussain","year":"2008","unstructured":"Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: soci\u00e9t\u00e9 fran\u00e7aise de greffe de mo\u00eblle osseuse-th\u00e9rapie cellulaire. J Clin Oncol 26:2512\u20132518. https:\/\/doi.org\/10.1200\/jco.2007.13.5533","journal-title":"J Clin Oncol"},{"key":"3909_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/bmt.2009.240","volume":"45","author":"SC Lee","year":"2010","unstructured":"Lee SC, Kim SJ, Lee DH, Kim WS, Suh C, Won JH (2010) Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 45:801\u2013802. https:\/\/doi.org\/10.1038\/bmt.2009.240","journal-title":"Bone Marrow Transplant"},{"key":"3909_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cncr.11035","volume":"97","author":"Y Shibamoto","year":"2003","unstructured":"Shibamoto Y, Hayabuchi N, Hiratsuka J, Tokumaru S, Shirato H, Sougawa M, Oya N, Uematsu Y, Hiraoka M (2003) Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97:128\u2013133. https:\/\/doi.org\/10.1002\/cncr.11035","journal-title":"Cancer"},{"key":"3909_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/jrr\/rrv085","volume":"57","author":"M Iwabuchi","year":"2016","unstructured":"Iwabuchi M, Shibamoto Y, Sugie C, Ayakawa S, Ogino H, Baba F (2016) Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience. J Radiat Res 57:164\u2013168. https:\/\/doi.org\/10.1093\/jrr\/rrv085","journal-title":"J Radiat Res"},{"key":"3909_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.wneu.2015.03.062","volume":"84","author":"R Kumar","year":"2015","unstructured":"Kumar R, Laack N, Pollock BE, Link M, O\u2019Neill BP, Parney IF (2015) Stereotactic radiosurgery in the treatment of recurrent CNS lymphoma. World Neurosurg 84:390\u2013397. https:\/\/doi.org\/10.1016\/j.wneu.2015.03.062","journal-title":"World Neurosurg"},{"key":"3909_CR26","doi-asserted-by":"publisher","DOI":"10.3171\/sup.2006.105.7.133","author":"H Kenai","year":"2006","unstructured":"Kenai H, Yamashita M, Nakamura T, Asano T, Momii Y, Nagatomi H (2006) Gamma Knife surgery for primary central nervous system lymphoma: usefulness as palliative local tumor control. J Neurosurg. https:\/\/doi.org\/10.3171\/sup.2006.105.7.133","journal-title":"J Neurosurg"},{"key":"3909_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11060-005-7698-8","volume":"77","author":"M Sakamoto","year":"2006","unstructured":"Sakamoto M, Oya N, Mizowaki T, Araki N, Nagata Y, Takayama K, Takahashi JA, Kano H, Katsuki T, Hashimioto N, Hiraoka M (2006) Initial experiences of palliative stereotactic radiosurgery for recurrent brain lymphomas. J Neurooncol 77:53\u201358. https:\/\/doi.org\/10.1007\/s11060-005-7698-8","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03909-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03909-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03909-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T13:13:19Z","timestamp":1643980399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03909-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3909"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03909-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"type":"print","value":"0167-594X"},{"type":"electronic","value":"1573-7373"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Health Institutional Review Boards of Samsung Medical Center (No. 2021-02-001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent was waived because of the retrospective nature of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}